Ameritas Investment Partners’s Sana Biotechnology SANA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$38.6K Hold
13,411
﹤0.01% 2255
2025
Q4
$54.6K Buy
13,411
+459
+4% +$2.06K ﹤0.01% 2060
2025
Q3
$46K Hold
12,952
﹤0.01% 2193
2025
Q2
$35.4K Hold
12,952
﹤0.01% 2387
2025
Q1
$21.8K Hold
12,952
﹤0.01% 2518
2024
Q4
$21.1K Hold
12,952
﹤0.01% 2608
2024
Q3
$53.9K Hold
12,952
﹤0.01% 2150
2024
Q2
$70.7K Buy
12,952
+3,686
+40% +$29.4K ﹤0.01% 1947
2024
Q1
$92.7K Hold
9,266
﹤0.01% 1788
2023
Q4
$37.8K Hold
9,266
﹤0.01% 2306
2023
Q3
$35.9K Buy
9,266
+2,648
+40% +$14.2K ﹤0.01% 2274
2023
Q2
$39.4K Hold
6,618
﹤0.01% 2189
2023
Q1
$21.6K Hold
6,618
﹤0.01% 2434
2022
Q4
$30.4K Hold
6,618
﹤0.01% 2363
2022
Q3
$39K Hold
6,618
﹤0.01% 2158
2022
Q2
$42K Hold
6,618
﹤0.01% 2105
2022
Q1
$55K Hold
6,618
﹤0.01% 2011
2021
Q4
$102K Hold
6,618
﹤0.01% 1672
2021
Q3
$149K Buy
6,618
+4,513
+214% +$94.7K 0.01% 1431
2021
Q2
$41K Buy
+2,105
New +$47.7K ﹤0.01% 2318

Other funds holding SANA

Ameritas Investment Partners's SANA Position: Q1 2026 in Review

Ameritas Investment Partners held its Sana Biotechnology (SANA) position steady in Q1 2026 at 13,411 shares worth $38.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2255.

Ameritas Investment Partners first reported a position in SANA in Q2 2021 and has held it in 20 quarters since. The position peaked at $149K in Q3 2021. 202 funds tracked by Wall St. Rank hold SANA as of Q1 2026.

  • Ameritas Investment Partners held 13,411 shares of Sana Biotechnology worth $38.6K as of Q1 2026.
  • Ameritas Investment Partners left its Sana Biotechnology share count unchanged in Q1 2026.
  • Sana Biotechnology made up ﹤0.01% of Ameritas Investment Partners's portfolio in Q1 2026, its #2255 holding.
  • Ameritas Investment Partners first reported a position in Sana Biotechnology in Q2 2021 and has held it in 20 quarters since.
  • Ameritas Investment Partners's Sana Biotechnology position peaked at $149K in Q3 2021.
  • 202 funds tracked by Wall St. Rank held Sana Biotechnology as of Q1 2026.

Based on Ameritas Investment Partners's 13F filing for Q1 2026, filed 13 May 2026.